Alk-Abello A/S (AKBLF) 142.5900 $AKBLF ALK's pa
Post# of 273254
Posted On: 09/23/2016 1:12:27 AM
Alk-Abello A/S (AKBLF) 142.5900 $AKBLF
ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
BusinessWire - Tue Jun 09, 6:01PM CDT
ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) today announced that its partner, MSD, known as Merck (NYSE: MRK) in the United States and Canada, has published positive results from a Phase II environmental exposure chamber trial evaluating the onset and dose-related efficacy of the house dust mite (HDM) sublingual allergy immunotherapy tablet (SLIT-tablet). The results appear in the latest printed edition of The Journal of Allergy and Clinical Immunology (JACI).
MRK: 63.02 (+0.32)
ALK: EAACI Annual Congress in Barcelona: Analysis of the International Guidelines for House Dust Mite Respiratory Allergy and the Need to Take an Integrated Approach.
BusinessWire - Mon Jun 08, 9:30AM CDT
A symposium sponsored by ALK (ALKBC / OMX: ALK B / AKABY / AKBLF) at the European Academy of Allergy and Clinical Immunology (EAACI) annual congress in Barcelona today has signalled the need for consensus in International Guidelines to take a more integrated approach to allergy immunotherapy treatment in respiratory allergy caused by house dust mites (HDM).
ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
BusinessWire - Tue Jun 09, 6:01PM CDT
ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) today announced that its partner, MSD, known as Merck (NYSE: MRK) in the United States and Canada, has published positive results from a Phase II environmental exposure chamber trial evaluating the onset and dose-related efficacy of the house dust mite (HDM) sublingual allergy immunotherapy tablet (SLIT-tablet). The results appear in the latest printed edition of The Journal of Allergy and Clinical Immunology (JACI). MRK: 63.02 (+0.32)
ALK: EAACI Annual Congress in Barcelona: Analysis of the International Guidelines for House Dust Mite Respiratory Allergy and the Need to Take an Integrated Approach.
BusinessWire - Mon Jun 08, 9:30AM CDT
A symposium sponsored by ALK (ALKB
C / OMX: ALK B / AKABY / AKBLF) at the European Academy of Allergy and Clinical Immunology (EAACI) annual congress in Barcelona today has signalled the need for consensus in International Guidelines to take a more integrated approach to allergy immunotherapy treatment in respiratory allergy caused by house dust mites (HDM). 
(0)
(0)Scroll down for more posts ▼